Moreover, a TNF-alpha antagonist therapy in rheumatoid arthritis patients led to enhanced PON1 levels concurrent with elevated anti-oxidative capacities of HDLs and lowered inflammatory status [47]. This evidence concerns the gene PON1 and rheumatoid arthritis.